Biomarkers in idiopathic pulmonary fibrosis
Y Zhang, N Kaminski - Current opinion in pulmonary medicine, 2012 - journals.lww.com
Current opinion in pulmonary medicine, 2012•journals.lww.com
The peripheral blood contains disease presence and outcome relevant information, and
suggests distinct biologically defined outcome trajectories in patients with IPF. Although
recently identified biomarkers should still be validated in multiple clinical contexts, there is
sufficient evidence to suggest that collection of peripheral blood biomarkers needs to be
incorporated in the design of drug studies and that some of these markers be clinically
evaluated in lung transplant prioritization.
suggests distinct biologically defined outcome trajectories in patients with IPF. Although
recently identified biomarkers should still be validated in multiple clinical contexts, there is
sufficient evidence to suggest that collection of peripheral blood biomarkers needs to be
incorporated in the design of drug studies and that some of these markers be clinically
evaluated in lung transplant prioritization.
Summary
The peripheral blood contains disease presence and outcome relevant information, and suggests distinct biologically defined outcome trajectories in patients with IPF. Although recently identified biomarkers should still be validated in multiple clinical contexts, there is sufficient evidence to suggest that collection of peripheral blood biomarkers needs to be incorporated in the design of drug studies and that some of these markers be clinically evaluated in lung transplant prioritization.
Lippincott Williams & Wilkins